Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Total Liabilities (2019 - 2025)

Benitec Biopharma has reported Total Liabilities over the past 7 years, most recently at $3.3 million for Q4 2025.

  • Quarterly results put Total Liabilities at $3.3 million for Q4 2025, up 6.17% from a year ago — trailing twelve months through Dec 2025 was $3.3 million (up 6.17% YoY), and the annual figure for FY2025 was $2.3 million, down 53.71%.
  • Total Liabilities reached $3.3 million in Q4 2025 per BNTC's latest filing, up from $2.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $7.6 million in Q1 2025 and bottomed at $1.4 million in Q2 2021.
  • Median Total Liabilities over the past 5 years was $3.2 million (2021), compared with a mean of $3.6 million.
  • The largest annual shift saw Total Liabilities surged 258.29% in 2021 before it tumbled 53.71% in 2025.
  • Over 5 years, Total Liabilities stood at $3.2 million in 2021, then dropped by 8.4% to $2.9 million in 2022, then skyrocketed by 102.1% to $5.9 million in 2023, then plummeted by 46.85% to $3.1 million in 2024, then grew by 6.17% to $3.3 million in 2025.
  • Business Quant data shows Total Liabilities for BNTC at $3.3 million in Q4 2025, $2.4 million in Q3 2025, and $2.3 million in Q2 2025.